COMMUNIQUÉS West-GlobeNewswire

SPARK NS and Haukeland University Hospital Announce Clinical Trial of D-Serine for Modifying Parkinson’s Disease Progression
20/01/2026
Previous research indicates that D-Serine is safe, tolerable, and holds promise as a potential neuroprotective treatment for Parkinson’s MENLO PARK, Calif. and BERGEN, Norway, Jan. 20, 2026 (GLOBE NEWSWIRE) -- SPARK NS [...]
Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure
20/01/2026
Preliminary 2025 thyroid testing revenue grew 21% over prior year Initial 2026 guidance of 16% growth in thyroid testing revenue All preferred stock converted to common stock Debt-free balance sheet and positive Net [...]
New Imprivata Survey Finds 85% of Healthcare IT Leaders Think Passwordless Authentication is Vital, but Adoption Lags Significantly
20/01/2026
Just 7% of organizations have fully adopted passwordless authentication, citing technical integration challenges and clinical training concerns WALTHAM, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Imprivata , a leading [...]
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
20/01/2026
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and clinical evidence [...]
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/01/2026
MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the [...]
Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis
20/01/2026
SANDWICH, United Kingdom, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food [...]
smartbax in-licenses lead antibacterial compound targeting Gram-negative infections from Aicuris
20/01/2026
Munich, Germany, Jan. 20, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the in-licensing of a new compound class from [...]
Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques
20/01/2026
Communiqué de presse Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques 20 janvier 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA ( [...]
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations
20/01/2026
Press Release Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations January 20, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124 [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
20/01/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 20 January 2026 at 08.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Nxera Pharma Establishes Metabolic Advisory Council to Advance Next-Generation Therapies for Obesity and Metabolic Disorders
20/01/2026
Council brings together leading global scientific and clinical experts in metabolic diseases to guide development of Nxera’s expanding proprietary pipeline Tokyo, Japan and Cambridge, UK, 20 January 2026 – Nxera Pharma [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 décembre 2025
19/01/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
Virbac: solide croissance en 2025 avec un chiffre d'affaires annuel en hausse de +7,9 % à pcc3, forte dynamique dans les catégories et pays clés
19/01/2026
Le chiffre d'affaires annuel 2025 atteint 1 465 M€ +7,9 % à taux de change et périmètre constants (pcc) comparé à 2024 +4,8 % à taux réels, impactés par des effets de change très défavorables, notamment en Amérique [...]
Virbac: solid 2025 dynamic with annual revenue up +7.9% at CERS3; with strong momentum in key categories and countries
19/01/2026
Full-year 2025 revenue reached €1,465m : +7.9% at constant exchange rate and scope (CERS) vs 2024 +4.8% at actual rates impacted by significant currency headwinds, particularly in Latin America, IMEA and the Pacific. [...]
GUERBET : Bilan semestriel du contrat de liquidité
19/01/2026
Bilan semestriel du contrat de liquidité Villepinte, le 19 janvier 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, présente aujourd’hui le bilan [...]
Metabo Drops 2026 [Latest Update]: Is It Legit? Liquid Delivery Science, Ingredient Research, and Informed Consumer Analysis
19/01/2026
Consumer verification searches for Metabo Drops have intensified as "Is It Legit?" queries and ingredient transparency questions reshape how buyers evaluate liquid metabolism drops — this 2026 analysis examines safety [...]
SAFE ORTHOPAEDICS FRANCHIT UNE ETAPE STRATEGIQUE : SIGNATURE DE SON PREMIER CONTRAT DE DISTRIBUTION AU BRESIL
19/01/2026
SAFE ORTHOPAEDICS FRANCHIT UNE ETAPE STRATEGIQUE : SIGNATURE DE SON PREMIER CONTRAT DE DISTRIBUTION AU BRESIL Fleurieux-sur-l’Arbresle – France – 19 janvier 2026 – 18h - Safe (FR001400ZU25 – ALSAF), annonce que sa [...]
Valneva fait un point sur son vaccin contre le chikungunya IXCHIQ®
19/01/2026
La Société retire volontairement ses demandes d’autorisation de mise sur le marché (BLA) et d’essais cliniques (IND) aux États-Unis Et continue d’évaluer le potentiel mondial du produit en fonction des besoins médicaux [...]
Valneva Provides Update on Chikungunya Vaccine IXCHIQ®
19/01/2026
Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and commercial attractiveness Saint Herblain (France), January 19, 2026 – Valneva SE [...]

Pages